158 related articles for article (PubMed ID: 20391956)
1. Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study.
Liguori S; Gottardi M; Micheletto G; Bruno L
Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):185-90. PubMed ID: 20391956
[TBL] [Abstract][Full Text] [Related]
2. Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control.
Tessaro L; Bandieri E; Costa G; Fornasier G; Iorno V; Pizza C; Pastacaldi G; Micheletto G
Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):113-21. PubMed ID: 20329570
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of oxycodone for management of acute pain episodes in chronic neck pain patients.
Ma K; Jiang W; Zhou Q; Du DP
Int J Clin Pract; 2008 Feb; 62(2):241-7. PubMed ID: 18070045
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
Nicholson B; Ross E; Sasaki J; Weil A
Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes.
Ong EC
Oncology; 2008; 74 Suppl 1():72-5. PubMed ID: 18758202
[TBL] [Abstract][Full Text] [Related]
11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
12. Patient-controlled analgesia versus oral controlled-release oxycodone - are they interchangeable for acute postoperative pain after laparoscopic colorectal surgeries?
Ho HS
Oncology; 2008; 74 Suppl 1():61-5. PubMed ID: 18758200
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
14. Use of oxycodone in polytrauma patients: the "Gemelli" experience.
Franceschi F; Marini M; Ursella S; Carbone L; Candelli M; Pignataro G; Gabrielli M; Santarelli L; Ojetti V; Giupponi B; Fiore V; Barbaro F; De Marco G; Buccelletti F; Mancini F; Roccarina D; Gigante G; Gasbarrini A; Gasbarrini G; Silveri NG
Eur Rev Med Pharmacol Sci; 2008; 12(2):123-6. PubMed ID: 18575163
[TBL] [Abstract][Full Text] [Related]
15. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study.
Singla N; Pong A; Newman K;
Clin Ther; 2005 Jan; 27(1):45-57. PubMed ID: 15763605
[TBL] [Abstract][Full Text] [Related]
16. [Controlled-release oxycodone--a therapeutic option for severe neuropathic pain. Two multicenter observational studies].
Wörz R; Frank M; Achenbach U
MMW Fortschr Med; 2003 Oct; 145 Suppl 3():71-6. PubMed ID: 15490770
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
18. Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.
Suzuki T; Morishita M; Ito E; Matsuura M; Tanaka R; Saito T
Am J Ther; 2008; 15(1):31-5. PubMed ID: 18223351
[TBL] [Abstract][Full Text] [Related]
19. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model.
Litkowski LJ; Christensen SE; Adamson DN; Van Dyke T; Han SH; Newman KB
Clin Ther; 2005 Apr; 27(4):418-29. PubMed ID: 15922815
[TBL] [Abstract][Full Text] [Related]
20. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
